共 50 条
- [41] Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial [J]. PharmacoEconomics - Open, 2024, 8 : 19 - 30
- [43] Empagliflozin in the treatment of heart failure with preserved ejection fraction [J]. INNERE MEDIZIN, 2022, 63 (07): : 808 - 809
- [49] Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial [J]. TERAPEVTICHESKII ARKHIV, 2021, 93 (12): : 1491 - 1497
- [50] Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial' [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (07) : 1323 - 1324